Associated Papers
Association Between the TP53 Polymorphisms and Breast Cancer Risk: An Updated Meta-Analysis.
Zhao L et al.
Frontiers in Genetics, 2022
Novel algorithms for efficient subsequence searching and mapping in nanopore raw signals towards targeted sequencing.
Han R et al.
Bioinformatics (oxford, England), 2020
Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.
Yadav P et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016
p21, p53, TP53BP1 and p73 polymorphisms and the risk of gastric cardia adenocarcinoma in a Chinese population.
Shao A et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 2015
Lessons and implications from association studies and post-GWAS analyses of cervical cancer.
Chen D et al.
Trends in Genetics : Tig, 2015
Genetic Polymorphism of MDM2 SNP309 in Patients with Helicobacter Pylori-Associated Gastritis.
Tongtawee T et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2015
MDM2 285G>C and 344T>A gene variants and their association with hepatocellular carcinoma: a Moroccan case-control study.
Rebbani K et al.
Infectious Agents and Cancer, 2014
Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis.
Gonçalves ML et al.
Springerplus, 2014
Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer.
Liu L et al.
Molecular Carcinogenesis, 2013
P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects.
Zhou C et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2013
Rapid detection of SNP (c.309T>G) in the MDM2 gene by the Duplex SmartAmp method.
Enokida Y et al.
Plos One, 2013
Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population?
Mandal RK et al.
Urologic Oncology, 2012
Association of P53 and ATM polymorphisms with risk of radiation-induced pneumonitis in lung cancer patients treated with radiotherapy.
Yang M et al.
International Journal of Radiation Oncology, Biology, Physics, 2011
MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
Willander K et al.
European Journal of Haematology, 2010
Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population.
Gangwar R et al.
Dna and Cell Biology, 2010
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Sinilnikova OM et al.
British Journal of Cancer, 2009
Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms.
Hancox RJ et al.
Human Genetics, 2009
Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer.
Misra C et al.
Molecular Carcinogenesis, 2009
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
Paulin FE et al.
Bmc Cancer, 2008
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X et al.
Human Mutation, 2006
[Correlation of polymorphisms of UDP-glucuronosyltransferase 1A7 gene to genetic susceptibility of lung cancer].
Feng FY et al.
Ai Zheng = Aizheng = Chinese Journal of Cancer, 2005
Indian studies on genetic polymorphisms and cancer risk.
Bag A et al.
Indian Journal of Cancer, 0